- EuroHYP EU Grant Award for Stroke
Proteome Sciences plc (“Proteome Sciences”) announces that Euro-HYP-1, a consortium of leading academic, clinical and industrial European partners in which it is a member, has been awarded a near €11m grant under the EU Framework 7 programme for new ground breaking research on the treatment of stroke. - Rainforest remedy could spell end of dental pain
An ancient Incan toothache remedy – for centuries handed down among an indigenous people in the rainforests of Peru – could be on the cusp of revolutionising worldwide dental practice. - Brain network provides hope for tinnitus sufferers
As Brain Awareness Week (12–18 March) gets underway in the UK, the preliminary findings from the latest tinnitus research suggest that hearing aids might help tinnitus sufferers; research is ongoing into the role the brain has, and how tinnitus symptoms are reflected in brain network activity. - CRT unveils ‘screen test’ for potential drugs to treat oestrogen positive breast cancer
Cancer Research UK and its commercial arm, Cancer Research Technology have developed a unique test to discover molecules that could lead to potential new treatments for oestrogen receptor (ER)-positive breast cancer. - £10 million boost for neglected tropical disease research at Dundee
The University of Dundee has received over £10 million from the Wellcome Trust in the fight against some of the world’s most neglected parasitic diseases, including support for a multi-million pound partnership with GlaxoSmithKline (GSK) to discover new drug treatments.
Featured Article
Saturday, 14 April 2012
Pharmacology/ Therapeutics
25 Hottest Articles
- The growing impact of click chemistry on drug discovery • Review article
Drug Discovery Today, Volume 8, Issue 24, December 2003, Pages 1128-1137 | Kolb, H.C.; Sharpless, K.B. - What makes a good drug target? • Review article
Drug Discovery Today, Volume 16, Issue 23-24, January 2011, Pages 1037-1043 | Gashaw, I.; Ellinghaus, P.; Sommer, A.; Asadullah, K. - The road ahead for large pharma: long-term science and innovation • Editorial
Drug Discovery Today, Volume 14, Issue 9-10, May 2009, Pages 439-441 | Lundberg, J.M.; Reilly, C. - The impact of aromatic ring count on compound developability - are too many aromatic rings a liability in drug design? • Review article
Drug Discovery Today, Volume 14, Issue 21-22, November 2009, Pages 1011-1020 | Ritchie, T.J.; Macdonald, S.J.F. - Learning lessons from drugs that have recently entered the market • Review article
Drug Discovery Today, Volume 16, Issue 9-10, May 2011, Pages 398-411 | Teague, S.J.
Drug trials
Latest News
- Drug combination domino effect destroys pancreatic cancer cells
Cancer Research UK scientists have revealed how a combination of two very different drugs, currently being tested in clinical trials, amplifies the destruction of pancreatic cancer cells, according to research published in the Journal of Experimental Medicine, today (Monday). - Convergence Pharmaceuticals announces start of Phase II study for CNV1014802
Convergence Pharmaceuticals today announced that the Phase II proof of concept study with CNV1014802 for treating pain associated with lumbosacral radiculopathy (LSR) has started. - Mental health problems after miscarriage continue after healthy birth
Women who experience depression and anxiety after a miscarriage continue to experience these symptoms even if they subsequently go on to have a healthy child. - AstraZeneca and Pfizer Join Cancer Research UK’s Stratified Medicine Programme
CANCER RESEARCH UK will be supported by AstraZeneca and Pfizer in a multimillion pound initiative to examine how genetic tests to improve cancer diagnosis can be best rolled out across the NHS.Cancer Research UK’s pioneering “Stratified Medicine Programme”* will also promote research into new targeted treatments by building a database of genetic information about tumours, treatments and survival rates that will enable researchers to design more effective cancer treatments in future. - GSK and Prosensa announce start of Phase III study of investigational Duchenne Muscular Dystrophy medication
GlaxoSmithKline (GSK) and Prosensa today announced that the first patient has commenced treatment in the Phase III study investigating GSK2402968, in ambulant boys with Duchenne Muscular Dystrophy (DMD), who have a dystrophin gene mutation amenable to an exon 51 skip
The value of in silico chemistry in the safety assessment of chemicals in the consumer goods and pharmaceutical industries
In this article Sandeep Modi, Michael Hughes, Andrew Garrow and Andrew White discuss limitations and strengths of in silico tools. Additionally, they look at different parameters that are necessary to make the best use of these tools, and also how to gain acceptance outside the modelling community and into the regulatory arena.
The authors propose an integrated workflow for combined use of data extraction, quantitative structure activity relationships and read-across methods. They discuss how the recent advances in this field can enable transition to a new paradigm of the discovery process, as exemplified by the Toxicity Testing in the 21st Century initiative.
Use of magnetic emulsion as a novel drug carrier for chemotherapeutic agents
Magnetic guidance of magnetic emulsion for site specific delivery was investigated in vitro and in vivo. The magnetic emulsion was characterized in vitro for its magnetic responsiveness using a constant flow apparatus, and its high retention by magnetic field was confirmed. After intravenous injection in rat, magnetic emulsions were localized to the predetermined site (lungs) by application of an electromagnet to the lungs. Similarly, 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea (methyl-CCNU) contained in the dispersed oily phase of the emulsions, was also concentrated at the target-site. Such preferential localization by magnetic means suggested that magnetic emulsions could become effective drug carriers with site specificity for the delivery of chemotherapeutic agents in cancer chemotherapy.
Keywords
- Drugs, drug delivery, magnetic emulsion;
- electromagnet;
- methyl-CCNU;
- cancer chemotherapy
Copyright © 1983 Published by Elsevier Ltd.
Subscribe to:
Comments (Atom)
